首页> 外文期刊>Cell >Structural Basis for Allosteric Ligand Recognition in the Human CC Chemokine Receptor 7
【24h】

Structural Basis for Allosteric Ligand Recognition in the Human CC Chemokine Receptor 7

机译:人CC趋化因子受体7中变构配体识别的结构基础7

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The CC chemokine receptor 7 (CCR7) balances immunity and tolerance by homeostatic trafficking of immune cells. In cancer, CCR7-mediated trafficking leads to lymph node metastasis, suggesting the receptor as a promising therapeutic target. Here, we present the crystal structure of human CCR7 fused to the protein Sialidase NanA by using data up to 2.1 angstrom resolution. The structure shows the ligand Cmp2105 bound to an intracellular allosteric binding pocket. A sulfonamide group, characteristic for various chemokine receptor ligands, binds to a patch of conserved residues in the Gi protein binding region between transmembrane helix 7 and helix 8. We demonstrate how structural data can be used in combination with a compound repository and automated thermal stability screening to identify and modulate allosteric chemokine receptor antagonists. We detect both novel (CS-1 and CS-2) and clinically relevant (CXCR1-CXCR2 phase-II antagonist Navarixin) CCR7 modulators with implications for multitarget strategies against cancer.
机译:CC趋化因子受体7(CCR7)通过稳态贩运免疫细胞平衡抗扰度和耐受性。在癌症中,CCR7介导的贩运导致淋巴结转移,表明受体作为有希望的治疗靶标。在这里,我们通过使用高达2.1埃分辨率的数据呈现给蛋白质唾液酸酶NANA的人CCR7的晶体结构。该结构显示与细胞内变形粘合剂结合的配体CMP2105。磺酰胺基团,各种趋化因子受体配体的特征,与跨膜螺旋7和螺旋8之间的GI蛋白结合区中的保守残余物蛋白结合。我们证明了结构数据如何与复合储存库和自动热稳定性组合使用筛选以鉴定和调节颠覆趋化因子受体拮抗剂。我们检测到新型(CS-1和CS-2)和临床相关(CXCR1-CXCR2相二对拮抗性Navarixin)CCR7调制器,具有对癌症的多元策略的影响。

著录项

  • 来源
    《Cell》 |2019年第5期|共19页
  • 作者单位

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    Paul Scherrer Inst Swiss Light Source Macromol Crystallog CH-5232 Villigen Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    F Hoffmann Roche Ltd Roche Innovat Ctr Basel Roche Pharma Res &

    Early Dev Therapeut Modal CH-4070 Basel Switzerland;

    Paul Scherrer Inst Dept Biol &

    Chem Lab Biomol Res Villigen Switzerland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号